

Point of Care Diagnostics Market by Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy), Platform (Microfluidic, Dipstick, RT-PCR, INAAT), Sample (Blood, Urine), Purchase (OTC, Rx), End User (Pharmacy, Hospitals, Home Care) - Global Forecast to 2028

Market Report | 2024-03-04 | 314 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The point of care diagnostics market is expected to reach USD 77.8 billion by 2028 from an estimated USD 49.7 Bn at a CAGR of 9.4% during the forecast period (2023-2028). The global rising burden of various health conditions including diabetes, cardiovascular diseases, infectious diseases and the growing demand for early detection and monitoring of these diseases are likely to boost the adoption of PoC testing devices. Additionally, technological advancements, healthcare policies promoting decentralized testing and emergence of small PoC manufacturers in emerging countries are likely to boost the growth of market during the forecast period.

"Infectious disease testing products segment of point of care diagnostics market to grow with the highest CAGR in the forecast period."

Based on products, the infectious disease testing products segment is anticipated to grow at a significant rate during the forecast period. Increasing number of infectious diseases such as HIV, tuberculosis, respiratory infections, coupled with the growing availability & awareness of POC testing for infectious diseases are likely to propel the segment growth.

"The clinical laboratories segment captured the largest market share of point of care diagnostics market in 2022"

On the basis of end users, the point-of-care and rapid diagnostics market is segmented into clinical laboratories; ambulatory care facilities and physicians' offices; pharmacies, retail clinics, and E-commerce platforms; hospitals, critical care centers, and urgent care centers; home care & self-testing; and other end users.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Clinical laboratories are the primary end users of point-of-care testing as they handle high volume of testing, accelerating the demand for point of care diagnostics devices. Moreover, the rapid expansion of clinical laboratories and presence of advanced PoC products in clinical laboratory settings are likely to promote the growth of the segment

North America accounted for the largest share of the point of care diagnostics market by region.

The global point of care diagnostics market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for PoC products and services, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The largest share of North America can be attributed to the rapid adoption of advanced diagnostic technologies, increases collaboration among rapid kits manufacturers and healthcare facilities, favorable reimbursement models, and well established healthcare infrastructure

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%

- By Designation: C-level-10%, Director-level-14%, and Others-76%

- By Region: North America-40%, Europe-32%, Asia Pacific-20%, Latin America-5%, and the Middle East & Africa-3%

The major players operating in the point-of-care diagnostics market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), and Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), EKF Diagnostics Holdings plc)

Research Coverage

This report studies the point-of-care diagnostics market based on product, platform, mode of purchase, sample, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

- Analysis of Key drivers (rising prevalence of infectious and chronic disease, growing adoption of self-testing kits, healthcare decentralization, rising number of CLIA-waiver PoC Tests), restraints (rising pricing pressure on PoC manufacturers, stringent regulatory approval procedures for new PoC devices), Opportunities (emerging markets, emerging technologies, such as microfluidics), Challenge (Training & education in low resource countries)

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the point-of-care diagnostics market

- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the point-of-care diagnostics market

- Market Development: Comprehensive information on lucrative emerging regions

- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the point-of-care diagnostics market

- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

leading market players.

Table of Contents:

1 INTRODUCTION 34

1.1 STUDY OBJECTIVES 34

1.2 MARKET DEFINITION 34

1.2.1 INCLUSIONS & EXCLUSIONS 35

1.3 STUDY SCOPE 37

1.3.1 MARKETS COVERED 37

1.3.2 REGIONS COVERED 38

1.3.3 YEARS CONSIDERED 38

1.3.4 CURRENCY CONSIDERED 38

1.4 KEY STAKEHOLDERS 39

1.5 SUMMARY OF CHANGES 39

1.6 RECESSION IMPACT 40

2 RESEARCH METHODOLOGY 41

2.1 RESEARCH DATA 41

FIGURE 1 RESEARCH DESIGN 41

2.1.1 SECONDARY RESEARCH 42

2.1.2 PRIMARY RESEARCH 43

2.1.2.1 Key data from primary sources 43

2.1.2.2 Key industry insights 44

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 44

FIGURE 3 BREAKDOWN OF PRIMARIES 45

2.2 MARKET SIZE ESTIMATION 45

FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 46

2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION 46

2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION 47

FIGURE 5 POINT-OF-CARE DIAGNOSTICS MARKET: MARKET SIZE ESTIMATION METHODOLOGY 48

2.2.3 PRIMARY RESEARCH VALIDATION 48

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 49

FIGURE 6 DATA TRIANGULATION METHODOLOGY 49

2.4 RESEARCH LIMITATIONS 50

2.5 RECESSION IMPACT ANALYSIS 51

TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH) 51

3 EXECUTIVE SUMMARY 52

FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 52

FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2023 VS. 2028 (USD MILLION) 53

FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2023 VS. 2028 (USD MILLION) 53

FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 54

FIGURE 11 GEOGRAPHIC SNAPSHOT OF POINT-OF-CARE DIAGNOSTICS MARKET 55

4 PREMIUM INSIGHTS 56

4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW 56

FIGURE 12 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 56

4.2 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 57

FIGURE 13 INFECTIOUS DISEASE TESTING PRODUCTS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 57

4.3 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (2022) 58

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 14	POC TESTING PRODUCTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	58
4.4	POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2023 VS. 2028	58
FIGURE 15	LATERAL FLOW ASSAYS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	58
4.5	POINT-OF-CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	59
FIGURE 16	CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD	59
5	MARKET OVERVIEW	60
5.1	INTRODUCTION	60
5.2	MARKET DYNAMICS	60
FIGURE 17	POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	60
5.2.1	DRIVERS	61
5.2.1.1	Rising incidence of infectious diseases	61
FIGURE 18	REGIONAL INCIDENCE OF HIV (2022)	61
5.2.1.2	Increasing prevalence of target conditions	62
5.2.1.3	Favorable government initiatives for POC testing	62
5.2.1.4	Rising number of CLIA-waived POC tests	63
TABLE 2	RECENT WAIVERS FOR PRODUCTS	63
5.2.2	RESTRAINTS	64
5.2.2.1	Pricing pressure on POC manufacturers	64
5.2.2.2	Stringent regulatory approval process for product commercialization	64
5.2.3	OPPORTUNITIES	65
5.2.3.1	High growth potential of emerging markets	65
5.2.3.2	Decentralization of healthcare	65
5.2.3.3	Innovative product development	66
5.2.4	CHALLENGES	66
5.2.4.1	Inadequate standardization with centralized lab methods	66
5.2.4.2	Limited awareness in emerging markets	67
5.2.4.3	Premium pricing of novel platforms	67
5.3	TECHNOLOGY ANALYSIS	68
5.3.1	POC TESTS WITH MULTIPLEXING CAPABILITIES	68
5.3.2	STROKE/CARDIAC MARKERS	68
5.3.3	THYROID TESTING	68
5.3.4	DNA TESTING	69
5.3.5	ENDOCRINE TESTING	69
5.3.6	RESPIRATORY DIAGNOSTICS	69
5.4	REGULATORY LANDSCAPE	70
TABLE 3	REGULATORY BODIES AND GOVERNMENT AGENCIES	70
5.4.1	KEY REGULATORY GUIDELINES	70
5.4.1.1	US	70
FIGURE 19	US: REGULATORY PROCESS FOR IVD DEVICES	71
5.4.1.2	Canada	72
FIGURE 20	CANADA: REGULATORY PROCESS FOR IVD DEVICES	72
5.4.1.3	Europe	72
FIGURE 21	EUROPE: REGULATORY PROCESS FOR IVD DEVICES	73
5.4.1.4	Japan	74
FIGURE 22	JAPAN: REGULATORY PROCESS FOR IVD DEVICES	74
5.4.1.5	China	74
TABLE 4	CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	75

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.4.1.6	India	75
FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES		
5.4.1.7	Brazil	76
FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES		
5.5	VALUE CHAIN ANALYSIS	77
FIGURE 25 VALUE CHAIN ANALYSIS-MAXIMUM VALUE ADDED DURING REGULATION & DISTRIBUTION STAGES		
5.6	SUPPLY CHAIN ANALYSIS	78
5.6.1	PROMINENT COMPANIES	78
5.6.2	SMALL & MEDIUM-SIZED ENTERPRISES	78
5.6.3	END USERS	78
FIGURE 26 SUPPLY CHAIN ANALYSIS		
5.6.4	PRICING ANALYSIS	79
TABLE 5 AVERAGE SELLING PRICE OF LEADING PRODUCTS, BY KEY PLAYER (USD)		
FIGURE 27 AVERAGE SELLING PRICE OF TOP 2 LEADING PRODUCTS, BY KEY PLAYER		
5.6.4.1	Average selling price trend	80
TABLE 6 AVERAGE PRICE OF GLUCOSE MONITORING & CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022 (USD)		
TABLE 7 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)		
TABLE 8 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)		
5.7	PORTER'S FIVE FORCES ANALYSIS	82
TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS		
5.7.1	BARGAINING POWER OF BUYERS	82
5.7.2	BARGAINING POWER OF SUPPLIERS	82
5.7.3	THREAT OF NEW ENTRANTS	82
5.7.4	THREAT OF SUBSTITUTES	83
5.7.5	INTENSITY OF COMPETITIVE RIVALRY	83
5.8	TRADE DATA	83
TABLE 10 IMPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018-2021 (USD MILLION)		
TABLE 11 EXPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018-2021 (USD MILLION)		
5.9	REIMBURSEMENT SCENARIO	84
TABLE 12 KEY MEDICARE CLINICAL LAB FEE SCHEDULE (CLFS) CODES FOR COVID-19 TESTING		
TABLE 13 MEDICARE HCPCS CODES FOR HIV TESTING		
5.10	PATENT ANALYSIS	85
FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012-DECEMBER 2023)		
5.10.1	ECOSYSTEM/MARKET MAP	86
FIGURE 29 ANALYSIS OF PARENT MARKET: IN VITRO DIAGNOSTICS MARKET		
5.10.2	KEY CONFERENCES & EVENTS	86
TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET: LIST OF KEY CONFERENCES & EVENTS (2023?2024)		
5.11	CASE STUDY ANALYSIS	87
5.11.1	DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I	87
TABLE 15 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS		
5.12	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	88
FIGURE 30 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX		
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	88
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	88
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE TESTING KITS & INSTRUMENTS		
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR POINT-OF-CARE TESTING KITS AND INSTRUMENTS (%)		
5.14	BUYING CRITERIA	89

FIGURE 32	KEY BUYING CRITERIA FOR POINT-OF-CARE TESTING KITS & INSTRUMENTS	89
TABLE 17	KEY BUYING CRITERIA FOR POC PRODUCTS	89
6	POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE	90
6.1	INTRODUCTION	91
TABLE 18	POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)	91
6.2	OTC TESTING PRODUCTS	91
6.2.1	GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET	91
TABLE 19	OTC TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	92
6.3	PRESCRIPTION-BASED TESTING PRODUCTS	92
6.3.1	RIISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET	92
TABLE 20	PRESCRIPTION-BASED TESTING PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)	93
7	POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM	94
7.1	INTRODUCTION	95
TABLE 21	POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021-2028 (USD MILLION)	95
7.2	LATERAL FLOW ASSAYS	95
7.2.1	RIISING ADOPTION OF TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET	95
TABLE 22	POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2021-2028 (USD MILLION)	96
7.3	IMMUNOASSAYS	96
7.3.1	UTILIZATION IN INFECTIOUS DISEASE TESTING TO SUPPORT MARKET GROWTH	96
TABLE 23	POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2028 (USD MILLION)	97
7.4	MICROFLUIDICS	97
7.4.1	GROWING TREND OF MINIATURIZATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET	97
TABLE 24	POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2021-2028 (USD MILLION)	98
7.5	DIPSTICKS	98
7.5.1	QUALITATIVE ANALYSIS OF MEDICAL CONDITIONS TO SUPPORT MARKET GROWTH	98
TABLE 25	POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2021-2028 (USD MILLION)	99
7.6	MOLECULAR DIAGNOSTICS	99
TABLE 26	POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2021-2028 (USD MILLION)	100
TABLE 27	POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)	100
7.6.1	RT-PCR	100
7.6.1.1	Rising cases of COVID-19 to boost demand	100
TABLE 28	POINT-OF-CARE DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021-2028 (USD MILLION)	101
7.6.2	INAAT	101
7.6.2.1	Cost benefits of INAAT to propel segment growth	101
TABLE 29	POINT-OF-CARE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021-2028 (USD MILLION)	102
7.6.3	OTHER TECHNOLOGIES	102
TABLE 30	POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)	102
8	POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE	103
8.1	INTRODUCTION	104
TABLE 31	POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)	104
8.2	BLOOD SAMPLES	104
8.2.1	HIGH UTILIZATION IN DISEASE DETECTION TO DRIVE MARKET	104
TABLE 32	POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2021-2028 (USD MILLION)	104
8.3	URINE SAMPLES	105
8.3.1	INCREASING PREVALENCE OF KIDNEY DISORDERS AND WIDE RANGE OF DIAGNOSTIC TARGETS TO BOOST DEMAND	105
TABLE 33	POINT-OF-CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2021-2028 (USD MILLION)	105
8.4	NASAL & OROPHARYNGEAL SWABS	105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.4.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET 105

TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2021-2028 (USD MILLION) 106

8.5 OTHER SAMPLES 106

TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021-2028 (USD MILLION) 106

9 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 107

9.1 INTRODUCTION 108

TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 108

9.2 GLUCOSE MONITORING PRODUCTS 109

TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) 109

TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 110

9.2.1 STRIPS 110

9.2.1.1 Ability to provide single-use measurement testing to drive market 110

TABLE 39 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2021-2028 (USD MILLION) 110

9.2.2 METERS 111

9.2.2.1 Ability to adjust therapeutic regimens daily to support market growth 111

TABLE 40 GLUCOSE MONITORING METERS MARKET, BY REGION, 2021-2028 (USD MILLION) 111

9.2.3 LANCETS & LANCING DEVICES 111

9.2.3.1 Provision of multiple depth penetration settings to boost demand 111

TABLE 41 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION) 112

9.3 COVID-19 TESTING PRODUCTS 112

9.3.1 RISING UPTAKE OF RT-PCR RAPID TESTS TO BOOST DEMAND 112

TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 113

9.4 CARDIOMETABOLIC MONITORING PRODUCTS 113

TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) 113

TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 114

9.4.1 CARDIAC MARKER TESTING PRODUCTS 114

9.4.1.1 Rising government initiatives for CVD research to drive market 114

TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 114

9.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 115

9.4.2.1 Technological advancements in monitoring products to support market growth 115

TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 115

9.4.3 HBA1C TESTING PRODUCTS 115

9.4.3.1 Favorable clinical outcomes with long-term monitoring to drive market 115

TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 116

9.5 INFECTIOUS DISEASE TESTING PRODUCTS 117

TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION) 117

TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 118

9.5.1 HIV TESTING PRODUCTS 118

9.5.1.1 Rising prevalence of HIV to drive market 118

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 50	POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	118
9.5.2	RESPIRATORY INFECTION TESTING PRODUCTS	119
9.5.2.1	Rising incidence of respiratory infections to drive market	119
TABLE 51	POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	119
9.5.3	HEPATITIS C TESTING PRODUCTS	119
9.5.3.1	Increasing prevalence of viral hepatitis to support market growth	119
TABLE 52	POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	120
9.5.4	HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS	120
9.5.4.1	High incidence of UTIs and surgical-site infections to boost demand	120
TABLE 53	POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	121
9.5.5	INFLUENZA TESTING PRODUCTS	121
9.5.5.1	Ability to identify A & B viral nucleoprotein antigens to drive market	121
TABLE 54	POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	121
9.5.6	TROPICAL DISEASE TESTING PRODUCTS	122
9.5.6.1	Rising incidence of malaria and dengue to support market growth	122
TABLE 55	POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	122
9.5.7	SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS	122
TABLE 56	POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	123
TABLE 57	POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	123
9.5.7.1	Syphilis testing products	123
9.5.7.1.1	Introduction of rapid tests to boost demand	123
TABLE 58	POINT-OF-CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	124
9.5.7.2	Human papillomavirus (HPV) testing products	124
9.5.7.2.1	Rising uptake of HPV diagnostics and RT-PCR to support market growth	124
TABLE 59	POINT-OF-CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	125
9.5.7.3	Chlamydia trachomatis testing products	125
9.5.7.3.1	Growing awareness of STI detection to boost demand	125
TABLE 60	POINT-OF-CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	126
9.5.7.4	Herpes simplex virus (HSV) testing products	126
9.5.7.4.1	Increasing incidence of HSV to support market growth	126
TABLE 61	POINT-OF-CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	126
9.5.8	TUBERCULOSIS	127
9.5.8.1	Rising prevalence of TB in underserved areas to support market growth	127
TABLE 62	POINT-OF-CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (USD MILLION)	127
9.5.9	CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS	127
9.5.9.1	Rising cases among hospitalized patients to boost demand	127
TABLE 63	POINT-OF-CARE DIAGNOSTICS MARKET FOR CDI, BY REGION, 2021-2028 (USD MILLION)	128
9.5.10	OTHER INFECTIOUS DISEASE TESTING PRODUCTS	128
TABLE 64	POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	128
9.6	COAGULATION MONITORING PRODUCTS	129
TABLE 65	POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	129

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 66	POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	130
9.6.1	PT/INR TESTING PRODUCTS	130
9.6.1.1	Ability to detect blood clots to support market growth	130
TABLE 67	POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	130
9.6.2	ACT/APTT TESTING PRODUCTS	131
9.6.2.1	Rising cases of dialysis and ESRD to boost demand	131
TABLE 68	POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	131
9.7	PREGNANCY & FERTILITY TESTING PRODUCTS	131
TABLE 69	POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	131
TABLE 70	POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	132
9.7.1	PREGNANCY TESTING PRODUCTS	132
9.7.1.1	Growing preference for home care testing to drive market	132
TABLE 71	POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	132
9.7.2	FERTILITY TESTING PRODUCTS	133
9.7.2.1	Growing focus on family planning to boost demand	133
TABLE 72	POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	133
9.8	TUMOR/CANCER MARKER TESTING PRODUCTS	133
9.8.1	INCREASING INCIDENCE OF CANCER AND RISING UPTAKE OF IMMUNOASSAYS TO PROPEL MARKET	133
TABLE 73	POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	134
9.9	URINALYSIS TESTING PRODUCTS	134
9.9.1	HIGH INCIDENCE OF RECURRENT UTIS TO DRIVE MARKET	134
TABLE 74	POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	135
9.10	CHOLESTEROL TESTING PRODUCTS	135
9.10.1	RISING OBESITY LEVELS AND INCIDENCE OF CVD TO BOOST DEMAND	135
TABLE 75	POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	135
9.11	HEMATOLOGY TESTING PRODUCTS	136
9.11.1	PREFERENCE FOR LABORATORY-BASED TESTS TO RESTRAIN MARKET	136
TABLE 76	POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2021-2028(USD MILLION)	136
9.12	DRUGS-OF-ABUSE TESTING PRODUCTS	136
9.12.1	RISING CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET	136
TABLE 77	POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	137
9.13	THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS	137
9.13.1	RISING CASES OF THYROID TO BOOST DEMAND	137
TABLE 78	POINT-OF-CARE DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	137
9.14	FECAL OCCULT TESTING PRODUCTS	138
9.14.1	INCREASING AWARENESS ON EARLY DISEASE DETECTION TO SUPPORT MARKET GROWTH	138
TABLE 79	POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	138
9.15	OTHER PRODUCTS	138
TABLE 80	POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	139

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10	POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER	140
10.1	INTRODUCTION	141
TABLE 81	POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	141
10.2	CLINICAL LABORATORIES	141
10.2.1	IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST DEMAND	141
TABLE 82	POINT-OF-CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)	142
10.3	AMBULATORY CARE FACILITIES AND PHYSICIANS' OFFICES	142
10.3.1	RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE TO DRIVE MARKET	142
TABLE 83	POINT-OF-CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS' OFFICES, BY REGION, 2021-2028 (USD MILLION)	143
10.4	PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS	143
10.4.1	ABILITY TO SUPPORT CHRONIC DISEASE MANAGEMENT TO BOOST DEMAND	143
TABLE 84	POINT-OF-CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2021-2028 (USD MILLION)	143
10.5	HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS	144
10.5.1	RAPID RESULTS AND END USERS OF POC DIAGNOSTICS	144
TABLE 85	POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)	144
10.6	HOME CARE SETTINGS AND SELF-TESTING	145
10.6.1	GROWING INCLINATION TOWARDS REMOTE-BASED CARE TO DRIVE MARKET	145
TABLE 86	POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2021-2028 (USD MILLION)	145
10.7	OTHER END USERS	146
TABLE 87	POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)	146
11	POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION	147
11.1	INTRODUCTION	148
TABLE 88	POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)	148
11.2	NORTH AMERICA	148
11.2.1	NORTH AMERICA: RECESSION IMPACT	148
FIGURE 33	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT	149
TABLE 89	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	150
TABLE 90	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	150
TABLE 91	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	151
TABLE 92	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	151
TABLE 93	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	152
TABLE 94	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	152
TABLE 95	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	153
TABLE 96	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021-2028 (USD MILLION)	153
TABLE 97	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)	154
TABLE 98	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	154
TABLE 99	NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)	155
11.2.2	US	155

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.2.2.1	Favorable government support and medical reimbursements to boost demand	155
TABLE 100	US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	156
11.2.3	CANADA	157
11.2.3.1	Rising incidence of diabetes and cancer to support market growth	157
TABLE 101	CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	158
11.3	EUROPE	159
11.3.1	EUROPE: RECESSION IMPACT	159
TABLE 102	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	159
TABLE 103	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	160
TABLE 104	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	161
TABLE 105	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	161
TABLE 106	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	162
TABLE 107	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	162
TABLE 108	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	163
TABLE 109	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021-2028 (USD MILLION)	163
TABLE 110	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)	163
TABLE 111	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	164
TABLE 112	EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)	164
11.3.2	GERMANY	165
11.3.2.1	Rising demand for innovative technologies to propel market	165
TABLE 113	GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	166
11.3.3	FRANCE	166
11.3.3.1	Growing public-private collaborations for product development to drive market	166
TABLE 114	FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	167
11.3.4	UK	168
11.3.4.1	Growing number of accredited diagnostic & hospital laboratories to propel market	168
TABLE 115	UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	169
11.3.5	ITALY	169
11.3.5.1	Increasing adoption of infectious disease diagnostics to drive market	169
TABLE 116	ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	170
11.3.6	SPAIN	170
11.3.6.1	Rising incidence of chronic diseases to support market growth	170
TABLE 117	SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	171
11.3.7	REST OF EUROPE	171
TABLE 118	REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	172
11.4	ASIA PACIFIC	173
11.4.1	ASIA PACIFIC: RECESSION IMPACT	173
FIGURE 34	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT	174
TABLE 119	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	175
TABLE 120	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	176
TABLE 121	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	177

TABLE 122	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	177
TABLE 123	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	178
TABLE 124	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	178
TABLE 125	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	179
TABLE 126	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021-2028 (USD MILLION)	179
TABLE 127	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)	179
TABLE 128	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	180
TABLE 129	ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)	180
11.4.2	JAPAN	181
11.4.2.1	Availability of advanced rapid flu tests to drive market	181
TABLE 130	JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	182
11.4.3	CHINA	182
11.4.3.1	Rising incidence of infectious diseases to drive market	182
TABLE 131	CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	183
11.4.4	INDIA	184
11.4.4.1	High burden of chronic diseases to propel market	184
TABLE 132	INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	185
11.4.5	AUSTRALIA	185
11.4.5.1	Increasing research investments for next-gen POC devices to fuel market	185
TABLE 133	AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	186
11.4.6	SOUTH KOREA	187
11.4.6.1	Growing awareness about advanced POC devices to boost demand	187
TABLE 134	SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	187
11.4.7	REST OF ASIA PACIFIC	188
TABLE 135	REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	189
11.5	LATIN AMERICA	190
11.5.1	LATIN AMERICA: RECESSION IMPACT	190
TABLE 136	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	190
TABLE 137	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	191
TABLE 138	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	191
TABLE 139	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	192
TABLE 140	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	192
TABLE 141	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	193
TABLE 142	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	193
TABLE 143	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021-2028 (USD MILLION)	193
TABLE 144	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)	194
TABLE 145	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	194
TABLE 146	LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)	195

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.5.2	BRAZIL	195
11.5.2.1	Rising prevalence of diabetes to support market growth	195
TABLE 147	BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	196
11.5.3	MEXICO	197
11.5.3.1	Rising incidence of cancer to drive market	197
TABLE 148	MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	197
11.5.4	REST OF LATIN AMERICA	198
TABLE 149	REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	198
11.6	MIDDLE EAST & AFRICA	199
11.6.1	MIDDLE EAST & AFRICA: RECESSION IMPACT	199
TABLE 150	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	199
TABLE 151	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	200
TABLE 152	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	200
TABLE 153	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	201
TABLE 154	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	201
TABLE 155	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	202
TABLE 156	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)	202
TABLE 157	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021-2028 (USD MILLION)	202
TABLE 158	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)	203
TABLE 159	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	203
TABLE 160	MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)	204
11.6.1.1	GCC Countries	204
11.6.1.1.1	Improvements in healthcare infrastructure to drive market	204
TABLE 161	GCC COUNTRIES: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	205
11.6.2	REST OF MIDDLE EAST & AFRICA	205
TABLE 162	REST OF AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	206
TABLE 163	REST OF MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	207
12	COMPETITIVE LANDSCAPE	208
12.1	INTRODUCTION	208
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	208
FIGURE 35	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET	209
12.3	REVENUE SHARE ANALYSIS	210
FIGURE 36	REVENUE ANALYSIS OF TOP FIVE PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET (2022)	210
12.4	MARKET SHARE ANALYSIS	211
FIGURE 37	POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)	211
12.5	COMPANY EVALUATION MATRIX	212
12.5.1	STARS	212
12.5.2	EMERGING LEADERS	212
12.5.3	PERVASIVE PLAYERS	212
12.5.4	PARTICIPANTS	212
FIGURE 38	COMPANY EVALUATION MATRIX	213
12.5.5	COMPANY FOOTPRINT	214

12.5.5.1	Product & regional footprint	214
TABLE 164	OVERALL FOOTPRINT	214
TABLE 165	PRODUCT FOOTPRINT	215
TABLE 166	REGIONAL FOOTPRINT	216
12.6	START-UP/SME EVALUATION MATRIX	217
12.6.1	PROGRESSIVE COMPANIES	217
12.6.2	RESPONSIVE COMPANIES	217
12.6.3	DYNAMIC COMPANIES	217
12.6.4	STARTING BLOCKS	217
FIGURE 39	START-UP/SME EVALUATION MATRIX	218
12.6.5	COMPETITIVE BENCHMARKING	219
TABLE 167	POINT-OF-CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES	219
12.7	COMPETITIVE SCENARIO	220
12.7.1	PRODUCT LAUNCHES & APPROVALS	220
TABLE 168	POINT-OF-CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-NOVEMBER 2023)	220
12.7.2	DEALS	221
TABLE 169	POINT-OF-CARE DIAGNOSTICS MARKET: DEALS (JANUARY 2020-NOVEMBER 2023)	221
12.7.3	OTHER DEVELOPMENTS	222
TABLE 170	POINT-OF-CARE DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020-NOVEMBER 2023)	222

Point of Care Diagnostics Market by Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy), Platform (Microfluidic, Dipstick, RT-PCR, INAAT), Sample(Blood, Urine), Purchase (OTC, Rx), End User (Pharmacy, Hospitals, Home Care) - Global Forecast to 2028

Market Report | 2024-03-04 | 314 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature